Information Provided By: 
Fly News Breaks for November 3, 2016
AER, AERI
Nov 3, 2016 | 15:53 EDT
RBC Capital analyst Adnan Butt says that Aerie Pharmaceuticals (AERI) is facing lower risk and has a greater chance of being acquired than at any time in its history, since its Rhopressa drug looks poised to be approved, while its preparing to release a second set of Phase III data for its Roclatan drug. The analyst says that Roclatan could be best in class. He keeps a $54 price target and Outperform rating on the name and recommends buying the shares. This note corrects an earlier one that mistakenly referenced AerCap (AER) in its title.
News For AERI;AER From the Last 2 Days
There are no results for your query AERI;AER
